Fundz

Who to call at Vor Biopharma Inc., and when

Fundz watches for the moments Vor Biopharma Inc. starts buying, and tells you who to reach.

  • An alert the day Vor Biopharma Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vor Biopharma Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Vor Biopharma Inc.. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

Vor Biopharma Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

www.vorbiopharma.com
Filed: Nov 3, 2025Cambridge, MassachusettsCIK: 0001817229Other
Full company profileView on SEC.gov

Leadership shakeup: 3 executive changes at Vor Bio in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

Vor Biopharma amended the employment agreement of Chief Development Officer Dr. Qing Zuraw, adding pro-rated 2025 and possibly 2026 target bonuses as a lump sum on termination without cause, and extending similar severance to resignations after December 31, 2025. The company also announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer.

Key Takeaways

The amendment, dated November 2, 2025, adds a lump-sum payment of a pro-rated 2025 target bonus, and possibly a pro-rated 2026 target bonus, if the Chief Development Officer is terminated without caus

Dr. Zuraw would receive the same severance benefits if she resigns for any reason after December 31, 2025, which gives her a severance-based exit path tied to that date.

3 more takeaways

Related Filings (9)

9 more filings from Vor Biopharma Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateNov 3, 2025
Item5.02
CategoryExecutive Change
CIK0001817229
Accession #0001193125-25-261723
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
material agreementexecutive hire

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Vor Biopharma Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.